source
- Summit Therapeutics shares tumble 20% after interim Phase 3 miss for ivonescimabSummit Therapeutics saw its shares fall about 20% after the market close on Thursday. The decline came after an interim analysis of a Phase 3 trial for its cancer candidate ivonescimab failed to m…
- Two biotech firms raise $556 million in combined IPOsSeaport Therapeutics and Hemab Therapeutics launched initial public offerings on Thursday, together bringing in $556.4 million to fund further development of their drug pipelines. Hemab Therapeuti…